Intravascular Delivery of Biologics to the Rat Kidney.
The renal microvascular compartment plays an important role in the progression of kidney disease and hypertension, leading to the development of End Stage Renal Disease with high risk of death for cardiovascular events. Moreover, recent clinical studies have shown that renovascular structure and function may have a great impact on functional renal recovery after surgery. Here, we describe a protocol for the delivery of drugs into the renal artery of rats. This procedure offers significant advantages over the frequently used systemic administration as it may allow a more localized therapeutic effect. In addition, the use of rodents in pharmacodynamic analysis of preclinical studies may be cost effective, paving the way for the design of translational experiments in larger animal models. Using this technique, infusion of rat recombinant Vascular Endothelial Growth Factor (VEGF) protein in rats has induced activation of VEGF signaling as shown by increased expression of FLK1, pAKT/AKT, pERK/ERK. In summary, we established a protocol for the intrarenal delivery of drugs in rats, which is simple and highly reproducible.
Divisions of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic.
Federico
F
Franchi
Divisions of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic.
Xiang Yang
XY
Zhu
Divisions of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic.
Tyra A
TA
Witt
Divisions of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic.
Lilach O
LO
Lerman
Divisions of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic; rodriguez.m@mayo.edu.
Martin
M
Rodriguez-Porcel
D000818:Animals; D001688:Biological Products / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002404:Catheterization / Q000379:methods; D004195:Disease Models, Animal; D005260:Female; D007668:Kidney / Q000098:blood supply* / Q000187:drug effects* / Q000378:metabolism; D007674:Kidney Diseases / Q000188:drug therapy / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage* / Q000493:pharmacokinetics
D001688:Biological Products; D011994:Recombinant Proteins; D042461:Vascular Endothelial Growth Factor A; C467498:vascular endothelial growth factor A, rat
Am J Physiol Renal Physiol. 2001 Nov;281(5):F948-57
11592952
Am J Pathol. 2010 Aug;177(2):632-43
20616344
Can J Cardiol. 2011 Jul-Aug;27(4):468-80
21550203
J Am Soc Nephrol. 2002 Mar;13(3):806-16
11856789
J Am Soc Nephrol. 2001 Jul;12(7):1434-47
11423572
J Am Soc Nephrol. 2001 Jul;12(7):1448-57
11423573
Nat Rev Nephrol. 2011 Apr;7(4):189-200
21364518
Circulation. 2002 Aug 27;106(9):1165-71
12196346
Mayo Clin Proc. 2011 Jul;86(7):649-57
21719621
Am J Kidney Dis. 2000 Oct;36(4):752-8
11007677
Am J Physiol Renal Physiol. 2012 May 15;302(10):F1342-50
22357917
Am J Pathol. 1986 Mar;122(3):462-8
3953769
Circ Cardiovasc Interv. 2012 Oct;5(5):720-8
23048054